कृपया अन्य खोज का प्रयास करें
As of June 4, 2021, Boston Therapeutics, Inc. was acquired by Nanomix, Inc., in a reverse merger transaction. Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. The company’s lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. It also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
J. Fraser Stoddart | - | - | Member of Scientific Advisory Board |
Carlos Bustamante | 71 | - | Member of Scientific Advisory Board |
Joseph Wang | - | - | Member of Technical Advisory Board |
Robert C. Haddon | - | - | Member of Technical Advisory Board |
Alexander Star | - | - | Member of Technical Advisory Board |
Matthew R. Lewin | - | - | Member of Medical Advisory Board |
Garrett P. Gruener | 65 | 2000 | Founder & Executive Chairman |
Marvin Wayne | - | - | Member of Medical Advisory Board |
Philip E. Bickler | - | - | Member of Medical Advisory Board |
Kristofer Pister | - | - | Member of Technical Advisory Board |
Muhammad Ashraful Alam | - | - | Member of Technical Advisory Board |
Eric S. Snow | - | - | Member of Technical Advisory Board |
Thomas Schlumpberger | - | 2022 | CEO & Director |
Gregory T. Schiffman | 65 | 2005 | Independent Director |
Philip G. Collins | - | - | Member of Technical Advisory Board |
Jerry L. Fiddler | 70 | - | Independent Director |
David Gerald Ludvigson | 71 | 2013 | CFO, President, Secretary & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है